

| | |
|--|----|
| Aydin, Ebru Anti-leukemic efficacy of NOX2 derived ROS inhibition in K-ras-induced leukemogenesis in mice | 36 |
| Baumann, Daniel Systematic screening of cytotoxic agents targeting oncogenic signaling pathways for combinatorial immunotherapy in tumor models | 37 |
| Bley, Nadine IGF2BP1 – a novel repressor of the adaptive immune response in ovarian cancer | 38 |
| Chiodoni, Claudia Trabectedin-induced reprogramming of tumor immune microenvironment creates the condition for ANTI-PD-1 inhibition of syngeneic osteosarcoma growth and metastasis | 39 |
| D'Alise, Anna Morena Personalized cancer vaccine based on ChAd vaccine improves over the anti-PD1 activity | 40 |
| Del Ben, Fabio A Method for detecting Circulating Tumor Cells based on the measurement of single-cell metabolism in droplet-based microfluidics | 41 |
| Elitas, Meltem Development of Microfabricated Tools to Investigate Immune Cell-Tumor Cell Interactions | 42 |
| Erb, Ulrike Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer | 43 |
| Freedman, Joshua Arming oncolytic adenoviruses to eliminate the tumour fibroblasts | 44 |
| Grees, Mareike Development of dendritic cell vaccination for combined melanoma immunotherapy | 45 |

| | |
|---|----|
| Gyori, David CD115+ myeloid cells promote tumor growth via the suppression of the adaptive immune system | 46 |
| Hansson, Johan Real life treatment patterns and outcomes in advanced Melanoma patients in Italy and Sweden: The development of a Multi-Country Database | 47 |
| Kather, Jakob Nikolas Spatial distribution patterns of blood vessels and immune cells in colorectal cancer tissue | 48 |
| Kloor, Matthias A frameshift peptide-based vaccine for MSI cancers: a phase I/IIa clinical trial | 49 |
| Krall, Nikolaus Unbiased profiling of the immunomodulatory properties of small molecules and soluble proteins | 50 |
| Kroon, Paula Mechanisms underlying curative responses to radio-immunotherapy | 51 |
| Kruger, Philipp A Systematic Approach to Chimeric Antigen Receptor Design | 52 |
| Kubon, Kristina Oncolytic Measles Virus for Tumor-Specific Vaccination | 53 |
| Oeztuerk, Selcen The Role of IDO-1 in Chronic Lymphocytic Leukemia | 54 |
| Pagani, Massimiliano Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor infiltrating T regulatory cells | 55 |
| Raute, Katrin Ex vivo expanded gamma delta T cells can kill patient-derived breast cancer stem cells (BCSC) in vitro and lead to decelerated tumor growth in BCSC-derived xenografts | 56 |

| | | |
|---|---|----|
| Rodriguez Barbosa, Jose Ignacio | Presenter: del Rio-Gonzalez, Maria-Luisa | |
| Crispr/Cas9 knock-out of CD160 gene to evaluate its function in NK cell-mediated rejection of transplantable hematopoietic tumor cells | | 57 |
| Schneidt, Viktor | | |
| Ex vivo study of the immune response against chronic lymphocytic leukemia cells after the treatment with antigen-armed antibodies | | 58 |
| Speck, Tobias | Presenter: Speck, Tobias; Heidbuechel, Johannes | |
| BiTE-armed oncolytic measles viruses for cancer immunovirotherapy | | 59 |
| Tarasiuk, Olga | | |
| Protein Disulfide Isomerase in ovarian cancer: a novel tumor-associated antigen and a potential target for cancer immunotherapy | | 60 |
| Thiesen, Hans-Juergen | | |
| Checkpoint-Inhibitor-Response: Stratification of HRO cancer patients suffering from clear cell renal cellular carcinoma (ccRCC) | | 61 |
| Tunali, Ilke | | |
| Quantitative imaging biomarkers predict immunotherapy response on non-small cell lung cancer patients | | 62 |
| Veerman, Rosanne | | |
| Allogeneic exosomes as a potential vehicle in cancer immunotherapy | | 63 |
| Veinalde, Ruta | | |
| Development of rational immunomodulation strategies for virotherapy | | 64 |
| Volkmar, Michael | | |
| Identification of T-cell Neoepitopes from PDAC Xenograft Exomes using a Hybrid Reference Genome | | 65 |

Wernet, Peter

An International Allogeneic Master Cell Bank of HLA homozygous Cord Blood derived non-viral iPSCs for Off-the-shelf matched CAR-T and Car-NK Cell Therapeutics as ATMPs for Cancer Immunotherapy 66

Younos, Ibrahim

Immunological effects of CD40 antibody (CP 870,893) treatment in resected melanoma patients 67